Concepedia

E. Läwitz

EL

Statistics

Publications

48

Citations

1.5K

H-Index

25

Active since

2006

Affiliations

Seno Medical (United States)(Current)

Cornell University

Johns Hopkins University

Clinical Research Institute

University of Florida

E. Läwitz is an author at Seno Medical (United States) specializing in antiviral therapy, viral hepatitis, and pharmacotherapy.

Publications per year

2006–2018

48

Publications

48

4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

Paul Y. Kwo, E. Läwitz, Jonathan McCone et al. · Journal of Hepatology · 2009 · 86 citations

, , +17

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Mark Sulkowski, David Gardiner, E. Läwitz et al. · Journal of Hepatology · 2012 · 80 citations

, , +16

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

F. Poordad, E. Läwitz, K.V. Kowdley et al. · Journal of Hepatology · 2012 · 65 citations

, , +12

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION

Hendrik W. Reesink, H.L.A. Janssen, Stefan Zeuzem et al. · Journal of Hepatology · 2012 · 61 citations

, , +14

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

K.V. Kowdley, E. Läwitz, F. Poordad et al. · Journal of Hepatology · 2013 · 56 citations · Full text

, , +12

1–5 of 48